<DOC>
	<DOCNO>NCT02005549</DOCNO>
	<brief_summary>This study evaluate effect Avastin ( 15mg/kg iv ) combination Docetaxel Xeloda , give pre-operative therapy patient primary breast cancer . Avastin administer every 3 week , first 5 cycle chemotherapy . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Chemotherapy Patients With Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>female patient , 1870years age ; histologicallyproven invasive breast cancer ; prior current neoplasm except nonmelanoma skin cancer , situ cancer cervix ; distant disease/secondary cancer . pregnant lactating woman ; preoperative local treatment breast cancer ; prior concurrent systemic antitumor therapy ; clinically significant cardiac disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>